Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by longonMJon Nov 10, 2018 5:03pm
89 Views
Post# 28955664

RE:RE:Next Week Will Be A 20-30% Decline

RE:RE:Next Week Will Be A 20-30% DeclineIn total and complete agreement with your point of view here.

Especially since this reporting quarter is for end of September and legalization only started on October 17th.  So, this is more of a transitional quarter than anything and sales will be strongly affected by when products were shipped IN ADVANCE of leagalization date along with how and whn these companies will book the sales.

It's definitely going to all be about the forward guidance spin more than the actual numbers themselves for this quarter.  As long as they show relatively strong triple digit percentage gains over the same quarter last year, they should be good to go.  Especially when the drinkables are scheduled to come on line in 2019 and the edibles the year after that.

Now, if you wanted all companies to be valued based upon their CURRENT financials only, like old line businesses approaching the end of their business life cycle, then I imagine huge growth companies like Amazon, Netflix, Tesla, etc. would all be trading at only mere fractions of where their current share prices are.


Juinvestments83 wrote: Hi stockemups, I see your point of view regarding the valuations. What is going to be a positive catalyst is future guidance and overall market growth potential. If this stock actually traded let’s say at an 8-10 multiple on EBITBA the SP would be significantly lower, however it’s all based on production, production capabilities and current dried inventory. I do own a position in ACB so I’m biased on the buy side. I see the SP consolidating from here and moving north as the supply chain issues are working themselves out. 


Just my opinion of course. Let me know what you think. 




Bullboard Posts